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Background: Despite present studies which suggested miR-133a as a promising biomarker for several cancers,
there still exist no articles concerning the validated clinical significance of miR-133a in non-small cell lung cancer
(NSCLC). Therefore, in this study, we targeted the correlation between miR-133a expression and clinicopathological
significance in NSCLC patients.
Methods: The expression of miR-133a in 125 cases of NSCLC and their paired adjacent non-cancerous tissues was
evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Meanwhile, the relationship
between miR-133a expression and several clinicopathological parameters and patient survival was analyzed.
Results: The relative level of miR-133a was 2.0108 ± 1.3334 in NSCLC tissues, significantly lower than that of the
adjacent non-cancerous lung tissues (3.6430 ± 2.2625, P = 0.019). The area under curve (AUC) of low expression of
miR-133a to diagnose NSCLC was 0.760 (95% CI: 0.702 ~ 0.819, P < 0.001). MiR-133a expression was negatively
correlated to lymphatic metastasis (r = −0.182, P = 0.042), tumor size (r = −0.253, P = 0.04), clinical TNM stages
(r = −0.154, P = 0.087), and EGFR protein expression (r = −0.612, P < 0.001).
Conclusions: MiR-133a serves as a tumor-suppressive miRNA in human NSCLC, and its downregulation suggests
deterioration in NSCLC patients.
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Lung cancer is the major cause of cancer mortality
worldwide with an approximation of 80% non-small cell
lung cancer (NSCLC) [1-3]. Although tremendous im-
provements have been made in diagnosis and treatment,
poor prognosis still exists in a large number of NSCLC
patients with a low 5-year overall survival rate and a
high recurrence rate [4-6]. Thus, it is utterly important
to discover reliable biomarkers of profound prognostic
value in NSCLC patients [7].
MicroRNAs (miRNAs) are short single-stranded
non-coding RNA molecules containing about 19 to 25
nucleotides, which regulate RNA silencing and post-
transcriptional regulation of gene expression [8,9]. The
malfunction of miRNAs is frequent in different* Correspondence: chen_gang_triones@163.com
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unless otherwise stated.carcinomas and plays a significant role in cancer pro-
gression [10-12]. It is generally believed that certain
miRNAs, which are aberrantly expressed, can serve as
potential biomarkers in terms of diagnosis and prognosis
[13-16]. Recent studies about miRNAs in NSCLC unveiled
that certain deregulated miRNAs are associated with the
regulation of cell growth, apoptosis, migration, and inva-
sion in NSCLC, such as miR-34a, miR-125a, miR-145,
miR-451, and miR-17-92 cluster [17,18]. The discoveries
suggested that the dysregulation of miRNA expression
might be strongly associated with oncogenesis and pro-
gression of NSCLC.
The expression of miR-133a was reported to be down-
regulated in various malignancies when cancerous tissue
was compared with normal adjacent tissue, including
bladder cancer, head and neck squamous cell carcinoma,
and colorectal cancer [19-21]. Also, the aberrant expres-
sion of miR-133a emerged among breast cancer, renal
cell carcinoma, and prostate cancer [22-24]. Nevertheless,
to date, there are very few studies attempting to expoundis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the clinicopathological parameters in NSCLC, except the
research by Wang et al. [25], in which only Kaplan-Meier
survival rate was taken into account. Further investiga-
tions are hence required to define the clinical significance
of miR-133a in NSCLC.Methods
Tissue samples
In the current study, we collected the formalin-fixed,
paraffin-embedded (FFPE) samples of cancerous and
non-cancerous adjacent lung tissues from 125 NSCLC
patients (75 males and 50 females; mean age, 61.10 years;
range, 23 to 90 years), who were hospitalized in the First
Affiliated Hospital of the Guangxi Medical University
(Nanning, Guangxi, China) between January 2012 and
February 2014. The research was approved by The Ethical
Committee of the First Affiliated Hospital of Guangxi
Medical University, China, and informed written consent
was obtained from all patients who participated. All tissue
samples were reviewed and diagnosed by two pathologists
independently. The clinicopathological characteristics
were summarized in Table 1. The defining criteria for age
and pathological grading were consulted from the report
by Li et al. [26] Also, the tumor size and TNM definition
criterion complies with the gauge from IASLC 2009 [27].EGFR status detection
We detected the EGFR status in the way previously re-
ported [28]. Briefly, for immunohistochemistry (IHC) to
detect EGFR protein expression, NSCLC tissue sections
were de-paraffinized and antigen retrieval was performed
with citrate buffer (pH 6.0) with 0.05% Tween-20. Slides
were incubated with primary EGFR polyclonal antibody
(sc-03, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) at 4°C overnight. The expression level of EGFR
protein was documented with the quickscore (Q score)
which is based on the percentage (P) of positive staining
tumor cells (0% to 100%) and the intensity (I) of staining
(0, complete nonappearance of staining; 1, weak cyto-
plasmic staining; 2, moderate and incomplete membran-
ous staining; 3, solid membranous staining). Both the
intensity and percentage of staining were assessed with
objective magnification × 10, while the distribution of
staining on membrane or cytoplasm was evaluated with
objective magnification × 40. The result of each case was
calculated by multiplying the percentage of positive
tumor cells with the intensity (Q = P × I; maximum = 3).
When Q score was ≥1, the result was regarded as posi-
tive. The Q score ≤2 was considered as low expression
of EGFR, while >3 was high expression. An overview of
all the IHC results was performed by two independent
pathologists (GC and PL). Two persons estimated thestaining individually, and discrepancies were determined
by consensus.
Concerning the EGFR gene amplification, gene copy
number per cell in NSCLC was investigated by FISH.
The LSI EGFR Spectrum Orange/CEP7 Spectrum Green
probe (Vysis, Abbott Laboratories, Chicago, IL, USA)
was used following the manufacturer instructions. FISH
signals were assessed under the fluorescence microscope
Olympus BX41 (Olympus, Tokyo, Japan) equipped with
single filters: DAPI, SpectrumOrange, and FITC as well
as a triple-filter DAPI/FITC/SpectrumOrange. FISH ana-
lysis was individualistically performed by two patholo-
gists who were unaware of the clinicopathological and
molecular features of patients. Negative results for FISH
in NSCLCs were determined if it was with no or low
genomic gain (≤four copies of gene in >40% of the cells),
and positive results included gene amplification and high
polysomy. Gene amplification was defined by the pres-
ence of tight gene clusters, a gene/chromosome per cell
ratio ≥2, or ≥15 copies of the genes per cell in ≥10% of
the analyzed cells, and high polysomy was identified as ≥
four copies of the gene in ≥40% of the cells.
As for the EGFR mutation detection, the QIAamp
DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany) was
used to extract DNA from paraffin-embedded tissues
and the operational tumor samples with histological
control for the presence of tumor cells (>75%) that was
obtained by trimming the non-cancerous tissue and nec-
rotic tissue. For mutational analysis of the kinase domain
of EGFR coding sequence, exons 18, 19, 20, and 21 were
amplified with specific pairs of primers, specific to the
flanking sequences of individual exon with the EGFR ref-
erence sequence (NM_005228.3, NCBI). The assay was
carried out according to the manufacturer’s protocol with
the ABI Step-one Plus real-time PCR system.
RT-qPCR
RNA isolation and RNA normalization were performed
as described formerly [29]. We applied reverse transcrip-
tion (RT) and qPCR kits based on precedents in order to
examine the expression of miR-133a as reported previ-
ously [30]. RT process for microRNA complied strictly
with the instructions of the manufacturer. Previously, we
discovered that the aggregation of miR-191 and miR-103
was the most stable housekeeping miRNA by using
NormFinder and geNorm. This combination was adopted
in the current study for the evaluation of miR-133a
expression. The primers for miR-133a, miR-191, and
miR-103 were included in TaqMan® MicroRNA Assays
(4427975, Applied Biosystems, Life Technologies, Grand
Island, NY, USA). Sequences of targeted miRNAs and ref-
erence miRNAs used were as follows: miR-133a (Applied
Biosystems Cat. No. 4427975-000458): UUGGUCCC-
CUUCAACCAGCUGU; miR-191 (Applied Biosystems
Table 1 Relationship between miR-133a and clinicopathological parameters in NSCLC xsÞð
Clinicopathological feature n miRNA-133a relevant expression (2−Δcq)
Mean ± SD t P value
Tissuea NSCLC 125 2.0108 ± 1.3334 6.949 <0.001
Adjacent non-cancerous lung 125 3.6430 ± 2.2625
Age (years) <60 57 1.8321 ± 1.2583 1.377 0.171
≥60 68 2.1606 ± 1.3846
Gender Male 75 1.9552 ± 1.2893 0.569 0.570
Female 50 2.0942 ± 1.4060
Smoke No 38 1.7792 ± 1.2891 1.565 0.122
Yes 30 2.3217 ± 1.5689
Tumor size (cm) ≤3 (pT1) 60 2.3058 ± 1.2512 −2.423 0.017
>3 (pT2, pT3, pT4) 65 1.7385 ± 1.3581
Lymph node metastasis No 56 2.2662 ± 1.3316 −1.951 0.053
Yes 69 1.8035 ± 1.3079
Vascular invasion No 90 2.0787 ± 1.3777 −0.912 0.364
Yes 35 1.8363 ± 1.2134
TNM I-II 54 2.2480 ± 1.3434 −1.749 0.083
III-IV 71 1.8304 ± 1.3063
Pathological gradingb I 17 2.2965 ± 1.5570 −1.074 0.345
II 78 1.8772 ± 1.3135
III 30 2.1963 ± 1.2459
Histological classificationc Adenocarcinoma 101 2.0638 ± 1.3517 4.980 0.008
Squamous carcinoma 23 1.6222 ± 0.9795
Large cell carcinoma 1 5.6000 ± 0.0000
EGFR amplification No 39 2.0159 ± 1.3763 −0.889 0.378
Yes 18 1.6533 ± 1.5483
EGFR protein expression Low 40 2.2843 ± 1.3288 −3.379 0.001
High 17 1.0006 ± 1.2706
EGFR mutation Wild type 44 1.9625 ± 1.4570 −0.590 0.557
Mutationd 13 1.6946 ± 1.3646
aPaired t student’s test was performed.
bOne-way analysis of variance (ANOVA) test was performed.
cRespective results of comparisons in histological classification were described as below:
Adenocarcinoma vs squamous carcinoma (t = 1.479, P = 0.142).
Adenocarcinoma vs large cell carcinoma (t = −2.603, P = 0.011).
Squamous carcinoma vs large cell carcinoma (t = −3.976, P = 0.001).
dEGFR mutation included short in-frame deletions in exon 19 and point mutations that result in a substitution of arginine for leucine at codon 858
(L858R) in exon 21.
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CAGCU; miR-103 (Applied Biosystems Cat. No. 4427975-
000439): AGCAGCAUUGUACAGGGCUAUGA. The re-
verse primers were also used for the reverse transcription
with TaqMan® MicroRNA Reverse Transcription Kit
(4366596, Applied Biosystems, Life Technologies, Grand
Island, NY, USA) in a total volume of 10 μl. We carried
out real-time qPCR for miRNA using Applied Biosystems
PCR7900. The expression of miR-133a was determined
with the formula 2−Δcq [31].Statistical analysis
We employed SPSS 20.0 for statistical analysis. Student’s
t test was conducted to discover the significance of dif-
ference between groups. We also adopted one-way ana-
lysis of variance (ANOVA) test to identify the
relationship between the expression level of miR-133a
and pathological grading and histological classification.
Receiver operating characteristic (ROC) curves were cre-
ated by SPSS 20.0 to evaluate how potent miR-133a is
when it came to distinguish the NSCLC tissues from
Figure 2 ROC curve of miR-133a for lung cancer. The area under
curve (AUC) of miR-133a was 0.760 (95% CI: 0.702 ~ 0.819, P < 0.001).
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by the Kaplan-Meier method while the log-rank test was
conducted to compare the survival status between
groups. It was considered to be statistically significant
when the P value calculated by two-tailed test was less
than 0.05.
Results
Decreased expression of miR-133a in NSCLC
The relative level of miR-133a in NSCLC tissues was
2.0108 ± 1.3334, which was significantly lower than that
in the adjacent non-cancerous lung tissues (3.6430 ±
2.2625, P = 0.019, Figure 1 and Table 1). Moreover, the
ROC curve was applied in order to evaluate the diagnos-
tic performance of miR-133a in NSCLC. The area under
curve (AUC) of miR-133a was 0.760 (95% CI: 0.702 ~
0.819, P < 0.001, Figure 2), and the optimal cut-off value
was 1.690.
Correlations between the miR-133a expression and
clinicopathological parameters in NSCLC
MiR-133a was identified to be associated with certain
clinicopathological parameters. The relative level of
miR-133a expression in patients with tumor greater than
3 cm (1.7385 ± 1.3581) was significantly lower when
compared to that in those with tumor less than or equal
to 3 cm (2.3058 ± 1.2512, P = 0.017, Figure 3A). We also
observed certain differences in histological classification,
with the expression level 2.0638 ± 1.3517 in adenocarcin-
oma, 1.6222 ± 0.9795 in squamous carcinoma, and
5.6000 ± 0 in large cell carcinoma. Statistical significance
existed in situations where we compared adenocarcin-
oma with large cell carcinoma (P = 0.011) and squamousFigure 1 The expression of miR-133a in lung cancer and non-cancerous
lung tissues. qRT-PCR was employed to detect the expression of
miR-133a in lung cancer tissue and adjacent non-cancerous lung
tissue. ***P< 0.001.carcinoma with large cell carcinoma (P = 0.001). As for
the association between miR-133a level and EGFR sta-
tus, we first detected EGFR expression by IHC. All 57
cases assessed for IHC showed positive EGFR staining
with the Q score more than 1. Among them, 40 had low
expression and 17 had high expression of EGFR.
Relatively lower level of miR-133a expression was also
perceived in cases of high EGFR protein expression
(2.2843 ± 1.3288) while higher level was detected in
those with low EGFR protein expression (1.0006 ±
1.2706, P = 0.001, Figure 3B). Even though considered to
be insignificant statistically, in NSCLC patients with
lymphatic metastasis, we detected a higher level of miR-
133a, that is, 2.2662 ± 1.3316 while there was a lower
level in those without lymphatic metastasis, namely
1.8035 ± 1.3079 with the P value 0.053. Furthermore, a
decreasing trend of miR-133a could be found in the
clinical TNM stages. The expression of miR-133a in
advanced stages (III and IV, 1.8304 ± 1.3063) was rela-
tively decreased when compared with that in early stages
(I and II, 2.2480 ± 1.3434, P = 0.083).
Meanwhile, Spearman correlation test was employed for
further analysis, which revealed the consistent relationship
between miR-133a expression and the following clinico-
pathological parameters: lymphatic metastasis (r = −0.182,
P = 0.042), tumor size (r = −0.253, P = 0.04), and EGFR
protein expression (r = −0.612, P < 0.001).
Nevertheless, other clinicopathological features which
proved to be independent of miR-133a expression were as
follows: age, gender, differentiation grades, pathological
types, smoke, vascular infiltration, metastasis, EGFR amp-
lification, or EGFR mutation status.
Figure 3 Correlations between the expression of miR-133a and some clinicopathological parameters in lung cancer. (A) tumor size; (B) EGFR
protein expression. *P < 0.05.
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ROC curves were applied to evaluate the predictive sig-
nificance of miR-133a level in NSCLC patients for clinico-
pathological factors. The AUC in terms of size was 0.646
(95% CI: 0.550 ~ 0.743, P = 0.005, cut-off value: 1.620, sen-
sitivity: 61.7%, 1-specificity: 33.8%) (Figure 4A). The area
under curve (AUC) in patients with lymphatic metastasis
was 0.606 (95% CI: 0.507 ~ 0.705, P = 0.043, cut-off value:
2.940, sensitivity: 32.1%, 1-specificity: 14.5%) (Figure 4B).
As for other clinicopathological factors, there appeared to
be inferior diagnostic significance.
Overall survival analysis of NSCLC patients
Among the 57 patients followed up, 27 had relatively
low miR-133a level (lower than the median level of 1.60)
while 30 possessed relatively high level of miR-133a ex-
pression. The high miR-133a expression group showed aFigure 4 ROC curves of miR-133a for clinicopathological factors of lung ca
0.646 (95% CI: 0.550 ~ 0.743, P = 0.005). (B) ROC curve of miR-133a level for lymsurvival time of 20.012 ± 3.132 months in contrast to
17.296 ± 3.424 months in low miR-133a expression
group. It is worth mentioning that there existed a dis-
tinct difference of 2.716 months in the survival between
the two groups even though no statistical significance of
miR-133a expression was shown in survival of NSCLC
(P = 0.325, Figure 5).
Discussion
To our knowledge, this study was the first one to illu-
minate the relationship between miR-133a and clinico-
pathological parameters in NSCLC. There were only two
publications concerning the role of miR-133a in NSCLC,
which concentrated more on its regulating mechanism
than the clinical significance [25,32]. In the perspective
of clinical significance, Wang et al. [25] concluded that
miR-133a expression levels indicate the clinical outcomencer. (A) ROC curve of miR-133a level for tumor size. The AUC was
phatic metastasis. The AUC was 0.606 (95% CI: 0.507 ~ 0.705, P = 0.043).
Figure 5 Kaplan-Meier curve for survival in miR-133a expression. No
statistical significance of survival emerged in patients with low or
high miR-133a expression (P = 0.325).
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factor merely based on the multivariable Cox regression
analysis. Moriya et al. [32] paid substantial attention to
the molecular mechanisms but none to its clinical
significance. What makes our current study potent and
novel is that we examined the miR-133a expression in
relatively larger sample sizes, 125 cases of NSCLC tis-
sues, and their paired non-cancerous lung tissues, which
minimized individual difference, and ran a full-panel
analysis between the expression levels of miR-133a and
clinicopathological parameters in NSCLC.
We found the role of miR-133a as a tumor suppressor
in NSCLC. The relative expression level of miR-133a
was significantly lower than that in the non-cancerous
lung tissues. Moreover, the ROC analysis results demon-
strated that miR-133a had a moderate diagnostic value
for NSCLC with the AUC of 0.760. Moriya et al. [32]
and Wang et al. [25] also reported the suppressive role
of miR-133a in NSCLC. In consideration of literatures
and the current study [25,32], it strongly suggests the
potential tumor-suppressive role of miR-133a and the pos-
sibility to be regarded as a promising diagnostic biomarker
as well as a target of treatment in NSCLC.
Our main focus in the current study lied in the correl-
ation between miR-133a and clinicopathological parame-
ters in NSCLC. To begin with, miR-133a was significantly
downregulated in NSCLC tissues with larger tumor diam-
eter (P = 0.017), which unveiled that miR-133a might cor-
relate with the growth of tumor in NSCLC positively.
However, although statistically significant, the correlation
between tumor size and miR-133a expression was quite
weak. Then, we came to the relationship between the
miR-133a expression and lymphatic metastasis. A higher
level of miR-133a, 2.2662 ± 1.3316, was shown in patientswith lymphatic metastasis while a lower level, 1.8035 ±
1.3079, was observed in those without lymphatic metasta-
sis. The difference should never be ignored despite the
boardline statistical significance (P = 0.053). A larger
cohort is needed to further determine the relationships
between miR-133a expression and tumor size as well as
lymphatic metastasis. It was actually supported by the
study of Wang et al. [25], in which they claimed that miR-
133a can inhibit cell invasiveness. Furthermore, the
expression of miR-133a suggested the deterioration of the
disease to certain degree in spite of inferior statistical
significance (P = 0.083), since the miR-133a expression in
advanced stages (III and IV, 1.8304 ± 1.3063) was lower
than that in early stages (I and II, 2.2480 ± 1.3434). As to
histological classification, we considered it to be fortuitous
owing to the sole case of large cell carcinoma, even
though there existed a statistical significance in the cases
of adenocarcinoma vs large cell carcinoma and squamous
carcinoma vs large cell carcinoma. The above results of
the study reveal a remarkable significance between miR-
133a and tumor growth, metastasis, and progression of
NSCLC. However, further study with a larger size of
cohort is required to confirm the current finding.
However, our results seem to contradict Wang et al.
[25] with regard to survival. According the their report,
the underexpression of miR-133a was significantly asso-
ciated with poor overall survival with a P value of
0.0409, which later inferred that miR-133a could be a
prognostic indicator when combined with the results of
multivariable Cox regression analyses. However, in our
study, there emerged no statistical significance of miR-
133a expression in the survival of NSCLC. We assume
that four main factors should account for the situation.
Firstly, the sample sizes were different with 57 followed-
up cases in our study and 112 in theirs. Secondly, the
conditions of patients also differed. For instance, all
cases of NSCLC patients used to analyze survival in our
study were adenocarcinoma, while it was not specified
which subtype the 112 cases in the study of Wang et al.
[25] were. Thirdly, different calculating methods of rela-
tive gene expression might also contribute to the dis-
crepancy. We used the formula 2−Δcq when determining
the expression of miR-133a while Wang et al. did not
specify the calculating method of gene expression in
their article [25]. Last but not least, endogenous controls
might result in the difference. In the study of Wang
et al. [25], they employed RNU48 as the endogenous
control while we adopted a combination of miR-191 and
miR-103 as the endogenous control in our research. We
hence plan to collect more followed-up cases and their
corresponding data for the purpose of further study in
terms of survival.
It would be hard for us to neglect the distinct correl-
ation between the miR-133a level and the expression of
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Spearman’s correlation. They were obviously correlated
negatively, which strongly backed the perspective of
Wang et al. [25], who assumed that several oncogenic
receptors in NSCLC cells might be direct targets of miR-
133a, including EGFR. Putative miR-133a binding sites
of EGFR have also been identified by computational
algorithms from several online miRNA-target gene predic-
tion softwares, including Targetscan (www.targetscan.org,
data not shown). Treating strategy using EGFR has gained
growing attention, which provides a significant response
and survival benefit. Nevertheless, resistance has already
emerged regardless of unexpanded usage [33,34]. Thus, it
is rational that a trend of resorting to miR-133a as a thera-
peutic strategy has become increasingly popular. Previ-
ously, we found that EGFR was a target gene of miR-146a
in NSCLS and we attempted to investigate the effect of
miR-146a in the treatment of NSCLC. MiR-146a did show
therapeutic efficiency on NSCLC cells to a certain degree.
Unfortunately, the impact was suboptimal [28], thus mak-
ing us curious about the potential of miR-133a as thera-
peutic strategy. Successive experiments are undergoing.
The molecular mechanisms between miR-133a and the
tumorigenesis of NSCLC may be concerned with other tar-
gets. Moriya et al. [32] stated that miR-133a regulates
ARPC5 and GSTP1 to perform a tumor-suppressive func-
tion. It remains a long way to go when it comes to the mo-
lecular mechanism of miR-133a and its target genes in
NSCLC.
Conclusions
The current research along with other related studies
firmly suggest that miR-133a serves as a tumor-
suppressive miRNA, which plays a crucial part in the
oncogenesis and progression of human NSCLC. The
downregulation of miR-133a indicates deterioration in
NSCLC patients. MiR-133a might be quite a promising
predictive biomarker as well as probable therapeutic
strategy for NSCLC. Our team intends to undergo fur-
ther in vitro and in vivo studies to illuminate the role
and mechanism of miR-133a in the malignant phenotype
of NSCLC cell lines.
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